Pharmacokinetics of (1 R,2 R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits

Cancer Chemotherapy and Pharmacology

Volumn 31, Issue 6, 1993, Pages 475-480

  Kizu, Ryoichi ^a   Higashi, Shin ichi ^a   Kidani, Yoshinori ^b   Miyazaki, Motoichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXALIPLATIN; PLATINUM; PLATINUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; MALE; NEPHROTOXICITY; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RABBIT; TISSUE DISTRIBUTION;

ANIMAL; ANTINEOPLASTIC AGENTS; CISPLATIN; COMPARATIVE STUDY; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; ORGANOPLATINUM COMPOUNDS; RABBITS; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0027408934     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685038     Document Type: Article

References (31)

1. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-l)oxalatoplatinum(II) in mice
2. Preparation and metabolism of a cisplatin/serum protein complex
3. The metabolites of platinum antitumor drugs and their biological significance
4. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin
5. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II)
6. Phase I study of oxaliplatin in patients with advanced cancer
7. A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP
8. Kinetics of cis-dichlorodiammineplatinum
9. Clinical kinetics of intact cisplatin and some related species
10. Preparative development of antitumor 1,2-cyclohexanediamine platinum complexes
11. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes
12. Antitumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers
13. Atomic absorption spectrophotometric determination of platinum in biological materials using nickel as an internal standard
14. Determination of (trans-1-1,2-diaminocyclohexane)oxalatoplatinum(II) in plasma and urine by high performance liquid chromatography
15. HPLC determination of cis-diamminedichloroplatinum(II) in plasma and urine with UV detection and column-switching
16. Trace analysis for cis-platinum anti-cancer drugs via LCEC
17. Alterations in the toxicity of cis-diamminedichloroplatinum(II) and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration
18. Plasma pharmacokinetics, urinary excretion, and tissue distribution of platinum following IV administration of cyclobutanedicarboxylatoplatinum-II and cis-platinum to rabbits
19. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119 875) to dogs
20. Cisplatin
21. Antitumor activity of 1-OHP in mice
22. A phase I trial of trans-1-1,2-diaminocyclohexane oxalato-platinum (1-OHP)
23. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatin
24. A new non nephro-, non cardio- and moderately hematotoxic platinum complex: 1-OHP or trans-1-1,2-diaminocyclohexane oxalato platinum: phase I and phase II trials
25. High-dose cisplatin in hypertonic saline
26. Cisplatin
27. Biliary excretion, renal handling and red cell uptake of cisplatin and CBDCA in animals
28. Comparative distribution and excretion of carboplatin and cisplatin in mice
29. Antitumor activity of a new platinum complex, oxalato(trans-1-1,2-diaminocyclohexane) platinum(II): new experimental data
30. Protein binding of five platinum compounds. Comparison of two ultrafiltration systems
31. A pharmacokinetic analysis program (MULTI) for microcomputer